• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

RABEPRAZOLE Drug Record

  • Summary
  • Interactions
  • Claims
  • RABEPRAZOLE chembl:CHEMBL1219 Approved

    Alternate Names:

    RABEPRAZOLE
    LY-307640
    ACIPHEX
    E3810
    E-3810 (PPI)
    LY307640
    E-3810
    ACIPHEX®
    PARIET®
    CLOFEZONE
    chembl:CHEMBL1219
    rxcui:114979
    drugbank:01129
    pubchem.compound:5029
    chemidplus:117976-89-3

    Drug Info:

    Drug Class gi anti-ulcer agents, proton-pump inhibitors
    Year of Approval 1999
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications Proton pump inhibitor
    (4 More Sources)

    Publications:

    Sugimoto et al., 2006, Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy., Clin. Pharmacol. Ther.
    Zhang L et al., 2010, The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people., J Clin Pharm Ther
    Take S et al., 2003, Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection., Am J Gastroenterol
    Langtry et al., 1999, Rabeprazole: a review of its use in acid-related gastrointestinal disorders., Drugs
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Carswell et al., 2001, Rabeprazole: an update of its use in acid-related disorders., Drugs
    Fujisaki et al., 1998, Effects of rabeprazole, a gastric proton pump inhibitor, on biliary and hepatic lysosomal enzymes in rats., Jpn. J. Pharmacol.
  • RABEPRAZOLE   ATP4A

    Interaction Score: 2.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Aciphex
    Novel drug target Established target

    PMIDs:
    10551440 11752352 11772142


    Sources:
    TdgClinicalTrial TEND TTD

  • RABEPRAZOLE   HEXB

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9593221


    Sources:
    NCI

  • RABEPRAZOLE   IL10

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16815316


    Sources:
    NCI

  • RABEPRAZOLE   IL1B

    Interaction Score: 0.56

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21054464 16815316 14638340


    Sources:
    PharmGKB

  • RABEPRAZOLE   ATP4B

    Interaction Score: 0.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TEND

  • RABEPRAZOLE   TNF

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16815316


    Sources:
    NCI

  • RABEPRAZOLE   ALOX15B

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RABEPRAZOLE   ALDH1A1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RABEPRAZOLE   MAPT

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RABEPRAZOLE   VDR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RABEPRAZOLE   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • RABEPRAZOLE   EHMT2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: RABEPRAZOLE

    • Version: 01-August-2011

    Alternate Names:
    RABEPRAZOLE Primary Drug Name

    Drug Info:
    Year of Approval 1999
    Drug Class gi anti-ulcer agents, proton-pump inhibitors

    Publications:

  • TdgClinicalTrial: RABEPRAZOLE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Proton pump inhibitor
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: RABEPRAZOLE

    • Version: 14-September-2017

    Alternate Names:
    C29410 NCI drug code

    Drug Info:

    Publications:
    Fujisaki et al., 1998, Effects of rabeprazole, a gastric proton pump inhibitor, on biliary and hepatic lysosomal enzymes in rats., Jpn. J. Pharmacol.
    Sugimoto et al., 2006, Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy., Clin. Pharmacol. Ther.

  • PharmGKB: rabeprazole

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Sugimoto et al., 2006, Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy., Clin. Pharmacol. Ther.
    Zhang L et al., 2010, The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people., J Clin Pharm Ther
    Take S et al., 2003, Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection., Am J Gastroenterol

  • DTC: RABEPRAZOLE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1219 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Rabeprazole

    • Version: 2020.06.01

    Alternate Names:
    D0KL4J TTD Drug ID

    Drug Info:

    Publications:

  • FDA: Rabeprazole

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1219

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21